Ehrlichia EtpE-C Polypeptide for Vaccine and Diagnostic Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostics and vaccines for Ehrlichiosis lack effectiveness due to the lack of identification of specific immunoreactive proteins that can trigger entry and infection of Ehrlichia species into host cells, making early diagnosis and treatment challenging, especially for emerging tick-borne zoonoses like human monocytic ehrlichiosis (HME).
Innovation Solution
Identification of the entry triggering protein of Ehrlichia (EtpE) and its conserved regions, particularly the C-terminal region (EtpE-C), which is critical for binding and infection, leading to the development of vaccines and diagnostic methods that utilize immunogenic polypeptides and recombinant vectors to elicit an immune response and detect antibodies across various Ehrlichia species.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostics and vaccines are used for Ehrlichiosis, then treatment is provided, but effectiveness is lacking due to inability to identify specific immunoreactive proteins
Solution Approach 1:
The patent utilizes the natural function of EtpE protein to trigger bacterial entry and infection, allowing the pathogen's own mechanism to become the basis for diagnostic and therapeutic intervention. By identifying and targeting this self-service entry mechanism, the invention creates effective diagnostics and vaccines without needing external complex identification systems
Solution Approach 2:
The invention extracts the specific immunoreactive EtpE protein from the complex Ehrlichia bacterial system. By isolating and focusing on this single critical protein responsible for entry and infection, the patent enables targeted diagnostics and vaccines that overcome the previous inability to identify specific immunoreactive targets
2Loss of time
If early diagnosis is attempted for HME, then treatment timing is improved, but diagnostic accuracy is limited without specific immunoreactive protein identification
Solution Approach 1:
By extracting and identifying the specific EtpE immunoreactive protein as the diagnostic target, the invention enables both early and accurate diagnosis. The specific protein marker allows for rapid detection without sacrificing precision, resolving the trade-off between speed and accuracy in HME diagnosis
3Reliability
If vaccines target specific immunoreactive proteins like EtpE-C, then protective immunity is elicited, but development complexity increases due to need for precise protein identification
Solution Approach 1:
The invention simplifies vaccine development by extracting and identifying the single critical EtpE-C protein as the immunogen. This focused approach on one specific immunoreactive region eliminates the need for complex multi-component formulations, reducing development complexity while maintaining high protective immunity
Solution Approach 2:
The patent applies local quality by focusing the vaccine formulation on the specific C-terminal region of EtpE (EtpE-C) that contains the critical immunoreactive epitopes. This localized targeting of the most effective immunogenic region enhances protective immunity while streamlining the vaccine design process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of EtpE-C in vaccines and diagnostics provides protective immunity and enables early detection of Ehrlichia infections, improving treatment outcomes by neutralizing bacterial entry and infection, and facilitating pan-diagnostic capabilities across multiple Ehrlichia species.
Implementation Method 1
the C-terminal region (EtpE-C), which is critical for binding and infection
Implementation Method 2
leading to the development of vaccines and diagnostic methods that utilize immunogenic polypeptides and recombinant vectors to elicit an immune response and detect antibodies
Implementation Method 3
vaccines and diagnostic methods that utilize immunogenic polypeptides and recombinant vectors
Data Source
AI summary
Disclosed are vaccines containing one or more immunogenic polypeptides derived from an EtpE protein from an Ehrlichia sp. or nucleic acid encoding these polypeptides. Also disclosed is a method for vaccinating a subject against Ehrlichia sp. that involves administering to the subject a composition comprising any of the disclosed vaccines. Also disclosed is a method for diagnosing and/or monitoring the treatment of Ehrlichiosis in a subject that comprising assaying a biological sample (e.g., blood, serum, or plasma sample) from the subject for the presence of an antibody that specifically binds an EtpE polypeptide. Also disclosed are methods for delivering a therapeutic or diagnostic agent to a cell in a subject that involves conjugating the agent, or a delivery vehicle comprising the agent, to polypeptide containing the C-terminal domain of an EtpE protein.